Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk provided significant funding to UK pharmacies for training, advertising and patient resources. Regulatory rulings found breaches of advertising rules and inadequate safeguards in ...

In December, Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of ...

Novo Nordisk cites 44 adverse events, including 38 serious cases and one death, linked to compounded liraglutide since 2017. Testing revealed impurities and fibril formation in unapproved ...

In December, Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances ...

Novo Nordisk also noted 44 documented adverse events associated with compounded liraglutide since 2017, including 38 serious cases and one death. Novo Nordisk warns that adding liraglutide to the ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts ... Novo’s older weight loss drug Saxenda and its insulin-degludec-based ...

Danish pharmaceutical leader Novo Nordisk(NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy, Rybelsus, and Saxenda. You'd think with such a robust ...